Sanofi India Ltd (BSE: 500674) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹6,775 Cr, it ranks #725 by market cap among the 6,137 Indian listed companies on FinBizNet, and #14 of 63 in Pharmaceuticals. At ₹2,772.80 (as of 25 Oct 2026), the share price is 43.4% below its 52-week high of ₹4,898.00 and 0.5% above its 52-week low of ₹2,758.20. The share price is down 40.9% over one year and down 18.2% over three months.
| Current Price | ₹2,772.80 |
|---|---|
| Market Cap | ₹6,775 Cr |
| BSE Code | 500674 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 20.7 |
| Return on Equity | 40.59% |
| Return on Assets | 19.81% |
| 52-Week Range | ₹2,758.20 – ₹4,898.00 |
| 1-Year Price Change | -40.9% |
| 3-Month Price Change | -18.2% |
| Beta (1Y) | 0.4 |
| Dividend Yield | 3.26% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.sanofi.com/en/india/investors |
| Revenue | ₹438 Cr |
|---|---|
| Net Profit | ₹84 Cr |
| Net Margin | 19.1% |
| EPS (Basic) | ₹36.26 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
1. Pharmaceutical Business-This segment offers pharmaceutical and related products.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Sanofi India Ltd | ₹6,775 Cr | 20.7 | 40.59% | ₹438 Cr | -40.9% |
Listed by market capitalisation. Ratios are shown for context only.
Sanofi India Ltd is trading at ₹2,772.80, with a market capitalisation of ₹6,775 Cr.
Sanofi India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sanofi India Ltd has a P/E of 20.7 and a return on equity of 40.59%.
Sanofi India Ltd is listed on the BSE under the scrip code 500674.
Sanofi India Ltd's share price is down 40.9% over one year and down 18.2% over three months. Its 52-week range is ₹2,758.20 to ₹4,898.00.
In Q1 FY27, Sanofi India Ltd reported revenue of ₹438 Cr and net profit of ₹84 Cr, with basic EPS of ₹36.26 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.